Two million UK study participants—drawn from 22 long-running cohorts—will have their decades of health, genetic, and lifestyle data pooled into a single platform to uncover what drives dementia and how to slow it down. Dementia research has been fragmented across small, separate studies, making it hard to spot subtle patterns or test drug targets at scale. This platform solves that by linking vast datasets that would otherwise remain siloed. The researchers also face a practical gap: how to measure cognitive decline cheaply in large populations, since clinical exams are too expensive and people losing motivation often skip tests. They will develop new assessment methods to solve this. If the platform succeeds, it could identify drug targets years earlier than current approaches allow. Even without a cure, slowing dementia so that people retain their dignity into old age would be a major win. The work is primarily fundamental science—understanding the earliest biological processes, genetic risks, and the body’s failure to repair itself. But the researchers are working directly with industry partners to accelerate any findings into therapies, rather than leaving discoveries on the lab bench.
View original technical description
The UK Dementias Platform (UKDP) is a radically new approach to dementias research, bringing together data from around 2,000,000 study participants from 22 cohorts to try and discover the causes of dementia and to find out ways of slowing it down. The platform has been funded to the level of £4.5M and invited to apply for a further £7.5M. To achieve our goals of discovering the causes of dementia and finding out ways to slow it down, we will analyse data collected over many decades from throughout the UK to identify targets for drugs studies. We will also enrich strategically selected cohorts to provide resources for dementias research in general. This will involve finding out how the early dementia processes begin, how our genes affect our risk of dementia and where our body goes wrong in maintaining and repairing itself. There are many practical challenges involved in doing this work including knowing how to assess dementia in large studies where having everyone examined by a doctor would be prohibitively expensive. Another challenge is how to measure cognitive decline in the population as when people begin to decline they are frequently less motivated to do cognitive tests. There are also important ethical issues surrounding this work and we have specific projects looking at ethical legal and social issues surrounding taking part in detailed measurement studies as well as in considering brain donation. To help make an impact as soon as possible, we will work closely with industry partners who are best placed to turn basic scientific knowledge into effective therapies. Even if we cannot cure dementia in the short term, it would count as a success if we found ways of slowing it down so that nobody need lose their dignity as they grew older.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know